Lupin Limited has informed the Exchange regarding a press release dated September 24, 2025, titled "Lupin Receives Tentative Approval from U.S. FDA for Bictegravir, Emtricitabine, andTenofovir Alafenamide Tablets".
Press Release Sep 24 2025
Filed with NSE ·
6ix hasn’t read this filing yet.
Earlier from Lupin
- Press Release Sep 17 2025
- Lupin Receives U.S. FDA Approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity, the First Product from its Nanomi's Long-Acting Injectable Platform
- Press Release Sep 03 2025
- Press Release Aug 20 2025
- Press Release Aug 12 2025
Later from Lupin
- Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO Capital
- Press Release Sep 30 2025
- Press Release Oct 01 2025
- Press Release Oct 03 2025
- Lupin Announces Plans to Build a New State-of-the-Art Manufacturing Facility in Coral Springs, Florida Extending its Long-Standing Commitment to America's Patients and Healthcare System
Follow Lupin into a list and get an email when it puts out news.
Follow Lupin